Login / Signup

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.

Yu FangNing SuQihua ZouYi CaoYi XiaLinquan TangXiaopeng TianPanpan LiuQing-Qing Cai
Published in: BMC medicine (2023)
ClinicalTrials.gov: NCT03906058.
Keyphrases
  • clinical trial
  • small cell lung cancer
  • squamous cell carcinoma
  • open label
  • randomized controlled trial
  • phase ii
  • combination therapy
  • smoking cessation
  • replacement therapy